[go: up one dir, main page]

MX367123B - Formulaciones de pruebas de testosterona proliposomal. - Google Patents

Formulaciones de pruebas de testosterona proliposomal.

Info

Publication number
MX367123B
MX367123B MX2014013450A MX2014013450A MX367123B MX 367123 B MX367123 B MX 367123B MX 2014013450 A MX2014013450 A MX 2014013450A MX 2014013450 A MX2014013450 A MX 2014013450A MX 367123 B MX367123 B MX 367123B
Authority
MX
Mexico
Prior art keywords
testosterone
disclosed
proliposomal
testosterone formulations
formulations
Prior art date
Application number
MX2014013450A
Other languages
English (en)
Other versions
MX2014013450A (es
Inventor
Guru V Betageri
Ramachandran Thirucote
Veeran Gowda Kadajji
Original Assignee
Univ Western Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49551459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367123(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Western Health Sciences filed Critical Univ Western Health Sciences
Publication of MX2014013450A publication Critical patent/MX2014013450A/es
Publication of MX367123B publication Critical patent/MX367123B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)

Abstract

Se divulgan formulaciones novedosas de testosterona en donde la testosterona se incorpora en un sistema de fosfolípido/colesterol para producir una dispersión proliposomal en polvo. Las dispersiones proliposomales en polvo del inventor se pueden formular con excipientes farmacéuticamente aceptables para formar composiciones farmacéuticas. Las formas de dosificación oral con cubierta entérica se divulgan ya que son métodos para el tratamiento para la terapia de reemplazo de testosterona.
MX2014013450A 2012-05-09 2013-05-09 Formulaciones de pruebas de testosterona proliposomal. MX367123B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644996P 2012-05-09 2012-05-09
PCT/US2013/040325 WO2013170012A2 (en) 2012-05-09 2013-05-09 Proliposomal testosterone formulations

Publications (2)

Publication Number Publication Date
MX2014013450A MX2014013450A (es) 2015-05-11
MX367123B true MX367123B (es) 2019-08-06

Family

ID=49551459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013450A MX367123B (es) 2012-05-09 2013-05-09 Formulaciones de pruebas de testosterona proliposomal.

Country Status (32)

Country Link
US (5) US8957053B2 (es)
EP (1) EP2846781B1 (es)
JP (3) JP6055088B2 (es)
KR (1) KR20150032939A (es)
CN (2) CN108096192A (es)
AP (1) AP2014008099A0 (es)
AR (1) AR091006A1 (es)
AU (2) AU2013259509B2 (es)
BR (1) BR112014027942A2 (es)
CA (1) CA2872779A1 (es)
CL (1) CL2014003034A1 (es)
CO (1) CO7240373A2 (es)
CR (1) CR20140561A (es)
DO (1) DOP2015000026A (es)
EA (2) EA201791738A1 (es)
EC (1) ECSP14030572A (es)
GE (1) GEP201706754B (es)
HK (2) HK1210409A1 (es)
IL (1) IL235464B (es)
IN (1) IN2014DN10383A (es)
MA (1) MA37610B1 (es)
MX (1) MX367123B (es)
MY (1) MY175305A (es)
NZ (2) NZ702634A (es)
PE (1) PE20150203A1 (es)
PH (1) PH12014502498A1 (es)
SG (2) SG11201407349UA (es)
TN (1) TN2014000467A1 (es)
TW (2) TWI614035B (es)
UA (1) UA115058C2 (es)
WO (1) WO2013170012A2 (es)
ZA (2) ZA201408996B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213440B2 (en) 2014-08-20 2019-02-26 Professional Compounding Centers Of America (Pcca) Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor
KR101682821B1 (ko) 2015-07-21 2016-12-06 서울대학교산학협력단 프로리포솜 제조방법
EA038653B1 (ru) * 2016-01-07 2021-09-29 Вестерн Юниверсити Оф Хелт Сайенсиз Составы для лечения рака мочевого пузыря
CN108601736A (zh) * 2016-01-08 2018-09-28 健康科学西部大学 前体脂质体十一酸睾酮制剂
KR102574139B1 (ko) 2016-07-07 2023-09-05 삼성전자주식회사 무선 충전 모드를 변경하는 장치 및 방법
CR20190274A (es) 2016-11-11 2019-07-29 Univ Western Health Sciences Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior
IL274579B2 (en) 2017-11-17 2025-04-01 Evonik Operations Gmbh Process for making a capsule with a coated hard shell
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
WO2020069450A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
EP3968969B1 (en) * 2019-05-15 2025-10-01 Evonik Operations GmbH Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine
CN113993508A (zh) * 2019-05-15 2022-01-28 赢创运营有限公司 用胶囊填充机制备具有基于纤维素或淀粉的包衣的填充硬壳胶囊的方法
AU2020329775A1 (en) * 2019-08-09 2022-02-24 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110747271B (zh) * 2019-12-02 2023-07-18 延边大学 关于pci术后血管损伤-再狭窄程度的标记物
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
CN111840240A (zh) * 2020-05-29 2020-10-30 仁和堂药业有限公司 一种非那雄胺制剂及其应用
CN112121003B (zh) * 2020-09-29 2022-02-01 江苏集萃新型药物制剂技术研究所有限公司 缓释制剂载药材料及其组合物、缓释制剂及其制备方法
WO2022245650A1 (en) * 2021-05-19 2022-11-24 Alberto Paz Orally administered compositions for cancer treatment
CN114668719B (zh) * 2022-02-21 2023-06-16 广东食品药品职业学院 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法
TW202417004A (zh) * 2022-09-16 2024-05-01 大陸商長春金賽藥業有限責任公司 類固醇激素磷脂組合物及其製備方法
CN117018211B (zh) * 2023-07-31 2025-09-09 沈阳药科大学 一种睾酮-胆固醇前药及制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
CA1337397C (en) 1988-09-29 1995-10-24 Hideo Nakajima Emulsified composition
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002051426A2 (en) 2000-12-22 2002-07-04 A Glenn Braswell COMPOSITIONS AND METHODS FOR TREATING SEXUAL DYSFUNCTIONS, IMPROVING SEXUAL ACTIVITY AND INCREASING TESTOSTERONE LEVELS, AND IMPROVING MUSCLE STRENGTH AND MASS
US6534080B2 (en) 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
EP1624857A2 (de) 2003-05-12 2006-02-15 Novosom AG Injizierbare depots aus liposomalen aggregaten zur wirkstoffverabreichung
JP4787165B2 (ja) 2003-11-05 2011-10-05 エラン ファーマ インターナショナル，リミティド 表面安定剤としてペプチドを有するナノ粒子組成物
US20060051406A1 (en) 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
US8246984B2 (en) 2005-12-06 2012-08-21 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US20070154403A1 (en) 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
NZ572308A (en) 2006-03-30 2011-09-30 Univ New York State Res Found Compositions of less immunogenic and long-circulating protein-lipid complexes
AU2008227852B2 (en) * 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2012058668A2 (en) * 2010-10-29 2012-05-03 Western University Of Health Sciences Ternary mixture formulations
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2013026002A1 (en) 2011-08-18 2013-02-21 Monosol Rx, Llc Steroid hormone delivery systems and methods of preparing the same

Also Published As

Publication number Publication date
CN104780914B (zh) 2018-02-09
US20160375036A1 (en) 2016-12-29
AU2013259509B2 (en) 2017-09-07
CN108096192A (zh) 2018-06-01
TN2014000467A1 (en) 2016-03-30
AU2013259509A1 (en) 2015-01-15
TW201350140A (zh) 2013-12-16
US20140112986A1 (en) 2014-04-24
IL235464A0 (en) 2014-12-31
US9445995B2 (en) 2016-09-20
EP2846781A2 (en) 2015-03-18
UA115058C2 (uk) 2017-09-11
HK1210409A1 (en) 2016-04-22
US9844557B2 (en) 2017-12-19
JP6055088B2 (ja) 2016-12-27
MA37610A1 (fr) 2016-07-29
MY175305A (en) 2020-06-18
HK1255929A1 (zh) 2019-09-06
CO7240373A2 (es) 2015-04-17
US20170065614A1 (en) 2017-03-09
US8957053B2 (en) 2015-02-17
HK1211499A1 (en) 2016-05-27
AU2017272249B2 (en) 2019-01-31
NZ721900A (en) 2018-01-26
NZ702634A (en) 2016-09-30
DOP2015000026A (es) 2015-06-15
SG11201407349UA (en) 2014-12-30
PE20150203A1 (es) 2015-02-01
TWI664982B (zh) 2019-07-11
TWI614035B (zh) 2018-02-11
EA028809B1 (ru) 2018-01-31
AU2017272249A1 (en) 2017-12-21
KR20150032939A (ko) 2015-03-31
US20180303850A1 (en) 2018-10-25
JP6368020B2 (ja) 2018-08-01
ZA201509340B (en) 2018-05-30
EA201791738A1 (ru) 2018-03-30
ECSP14030572A (es) 2015-11-30
CA2872779A1 (en) 2013-11-14
AP2014008099A0 (en) 2014-12-31
JP2017061552A (ja) 2017-03-30
US20150157572A1 (en) 2015-06-11
JP6208842B2 (ja) 2017-10-04
GEP201706754B (en) 2017-10-25
ZA201408996B (en) 2017-08-30
JP2015520751A (ja) 2015-07-23
EP2846781B1 (en) 2019-10-30
IL235464B (en) 2019-09-26
EP2846781A4 (en) 2016-03-30
MA37610B1 (fr) 2017-07-31
JP2018021062A (ja) 2018-02-08
SG10201702240TA (en) 2017-05-30
WO2013170012A3 (en) 2015-06-04
US9623033B2 (en) 2017-04-18
PH12014502498A1 (en) 2014-12-22
EA201492047A1 (ru) 2015-05-29
TW201831169A (zh) 2018-09-01
CN104780914A (zh) 2015-07-15
CR20140561A (es) 2015-02-12
MX2014013450A (es) 2015-05-11
BR112014027942A2 (pt) 2017-06-27
WO2013170012A2 (en) 2013-11-14
IN2014DN10383A (es) 2015-08-14
CL2014003034A1 (es) 2015-07-03
AR091006A1 (es) 2014-12-30

Similar Documents

Publication Publication Date Title
PH12014502498A1 (en) Proliposomal testosterone formulations
IN2014MN00987A (es)
IN2014MN00948A (es)
EP2670462A1 (en) Intranasal delivery devices
IN2014MN02049A (es)
IN2014MN00988A (es)
MX2013011655A (es) Forma de dosis unitaria para administracion oral.
IN2014MN00986A (es)
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
IN2012MN02591A (es)
IN2014MN02598A (es)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
IN2014DN06869A (es)
PH12014502065A1 (en) Vesicular formulations
IN2014DN03010A (es)
IN2014MN02133A (es)
JO3810B1 (ar) صيغ التستوستيرون الشحمية المساندة
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.

Legal Events

Date Code Title Description
FG Grant or registration